A new peer-reviewed study published in the British Journal of Pharmacology examines amylin analogues as a potential next wave of anti-obesity medications — a development worth watching for anyone currently on or considering GLP-1 drugs like Ozempic, Wegovy, Mounjaro, or Zepbound.
Why Researchers Are Looking Beyond GLP-1s
GLP-1 receptor agonists have transformed obesity treatment, but scientists are actively searching for additional tools. According to the study, public health systems face a major challenge due to the worldwide obesity epidemic, with the number of obese individuals increasing dramatically. The researchers note that even Switzerland — described in the paper as a relatively "lean" country — has seen obesity rates reach almost 50% of its adult population. This underscores what the authors call an urgent need for effective, safe, and widely available therapeutic interventions worldwide.
Amylin is a naturally occurring gut hormone, and researchers are now investigating synthetic analogues of it as a new class of anti-obesity therapy. The study frames these analogues as part of a broader strategy to develop treatments based on physiological gut hormones — the same scientific principle that underpins GLP-1 medications.
What Are Amylin Analogues and How Do They Differ?
Amylin is a hormone released alongside insulin from the pancreas in response to eating. Like GLP-1, it plays a role in regulating appetite and slowing gastric emptying. Amylin analogues are engineered versions of this hormone designed to amplify or mimic those effects in a more controlled, therapeutic way. While GLP-1 drugs target the GLP-1 receptor pathway, amylin analogues work through a distinct mechanism — meaning they could potentially be used on their own or, in the future, alongside existing GLP-1 therapies to enhance results.
Key takeaway: Amylin analogues represent a separate class of gut-hormone-based obesity treatment that could eventually complement or offer an alternative to GLP-1 drugs — but they remain in the research phase and are not yet approved for obesity treatment.
What This Means for Current GLP-1 Users
For people currently taking semaglutide or tirzepatide, this research does not change anything about their treatment today. However, it signals that the obesity medication landscape is actively expanding. If you have found GLP-1 therapies effective but are concerned about side effects, cost, or long-term maintenance, amylin-based options may eventually provide additional choices. It is also possible that future combination therapies — pairing GLP-1 and amylin pathways — could offer greater weight loss than either approach alone, though the source material does not make specific claims about combination outcomes.
What to Watch Next
The publication in the British Journal of Pharmacology is a scientific review, not a clinical trial result, so amylin analogues as an obesity treatment are still in earlier stages of investigation. Key milestones to follow include the launch or results of human clinical trials, regulatory filings with bodies such as the FDA or EMA, and any announcements from pharmaceutical companies developing compounds in this class. The field is moving quickly, and the success of GLP-1 drugs has intensified industry and academic interest in the broader gut-hormone space.
Frequently Asked Questions
As always, any changes to your weight management plan — including curiosity about emerging treatments — are best discussed with your prescriber, who can help you evaluate options based on your individual health history and goals.
- Peer-reviewed journal article, 'Amylin analogues as a novel perspective in anti-obesity therapy,' British Journal of Pharmacology, date not specified in source material.